Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda to Revamp Sales Offices as Japan Shifts to Community-Based Care System
February 20, 2018
- Lenvima OK’ed for UK Health Coverage in Thyroid Cancer
February 19, 2018
- Oncolys Invests in US Immuno-Oncology Startup
February 19, 2018
- Sumitomo Dainippon Halts Development of FXR Agonist in Japan, South Korea
February 16, 2018
- Daiichi Sankyo Files Mirogabalin in Japan for PNP
February 16, 2018
- Global Brands Drive Otsuka’s Pharma Sales in 2017
February 15, 2018
- Astellas Picks Up US Upstart, Grabs Full Access to Universal Donor Cell Technology
February 15, 2018
- Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
- Teijin, SanBio Terminate License Agreement for Stroke Treatment; Development and Marketing Rights to Revert to SanBio
February 15, 2018
- Lonasen Patch Hits PIII Primary Target in Japan, Filing Planned in 1st Half of FY2018: Sumitomo Dainippon, Nitto Denko
February 15, 2018
- New Dosage Strength Approved for Enbrel Pen: Pfizer
February 14, 2018
- Adcetris Filed in Japan for Frontline Hodgkin’s Lymphoma: Takeda
February 14, 2018
- Zytiga Shows Consistent Efficacy in Japanese High-Risk mHNPC Patients
February 14, 2018
- New IITs for Oncolytic Virus to Begin for Head and Neck Cancer, Sarcoma: Oncolys
February 13, 2018
- Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
February 13, 2018
- 2018 to See Transition to “Leap Phase” in Kyowa Kirin’s Midterm Plan: President
February 13, 2018
- Hiroshima Couple Arrested for Counterfeit Harvoni Case
February 9, 2018
- Nipro Grabs Rights to TC BioPharm’s CAR-T Therapy
February 9, 2018
- Kyowa Kirin Logs Higher Earnings on Milestones, Lower R&D Costs
February 9, 2018
- Ethical Drug Sales Up 2.1% in December on Cancer Meds, SGLT2
February 9, 2018
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…